Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan Aponvie Prior Auth Coverage …
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MBP 299.0

    Aponvie (aprepitant) — Medical Benefit Pharmaceutical Policy

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MBP 299.0 alerts

    Get alerted when Policy MBP 299.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This medical benefit pharmaceutical policy governs prior authorization and coverage criteria for Aponvie (aprepitant) for prevention of postoperative nausea and vomiting (PONV) for Geisinger Health Plan members across applicable commercial, Medicare, and CHIP lines of business.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAponvie (aprepitant) — Medical Benefit Pharmaceutical Policy
    Policy CodePolicy MBP 299.0
    Change TypeNo material change
    Effective Date
    Last ReviewOct 27, 2025
    Next Review DateSep 3, 2025
    Key ActionObtain prior authorization from the Medical Director or designee for a one-time administration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum member age for coverage
    One-timeauthorization duration
    32 mgvial strength / limit
    One vial/dayquantity limit
    Commercial, Medicare, CHIPlines of business

    Coverage Criteria for Aponvie (aprepitant)

    Initial authorization criteria

    Aponvie (aprepitant) will be considered medically necessary when ALL of the following are met:

    Age: Medical record documentation that the member is 18 years of age or older>=18 years
    Indication: Medical record documentation of use for prevention of post-operative nausea and vomiting (PONV)
    Prescriber: Medical record documentation that the medication is prescribed by a surgeon or anesthesiologist

    Eligibility and contract-specific benefit limitations and exclusions apply to coverage of Aponvie (aprepitant). Line of business benefit documents (for example, Commercial, Medicare, or CHIP plan benefit booklets) take precedence and will supersede the statements in this policy when there is a conflict.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAponvie (aprepitant) — Medical Benefit Pharmaceutical Policy
    Policy CodePolicy MBP 299.0
    Change TypeNo material change
    Effective Date
    Last ReviewOct 27, 2025
    Next Review DateSep 3, 2025
    Key ActionObtain prior authorization from the Medical Director or designee for a one-time administration.
    SourceLink
    On This Page
    Coverage Criteria for Aponvie (aprepitant)Provider Requirements and Action ItemsInitial TherapyQuantity and Dosing LimitsSite of Care ConsiderationsDefinitionsBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Provider Requirements and Action Items

    Prior Authorization

    Prior authorization required

    Prior authorization is required and must be obtained from the Medical Director or their designee. Approved requests will be authorized one time for one administration of Aponvie.

    Step Therapy

    No step therapy requirements

    There are no step therapy requirements for Aponvie specified in this policy.

    Documentation Required

    Required medical record documentation

    Document in the medical record that the member is at least 18 years old, that the medication is being used for prevention of postoperative nausea and vomiting (PONV), and that the prescriber is a surgeon or anesthesiologist.

    • Age: medical record evidence member is 18 years of age or older
    • Indication: documentation the use is for prevention of post-operative nausea and vomiting (PONV)
    • Prescriber: documentation that the medication is prescribed by a surgeon or anesthesiologist
    Denial Risk

    Denial triggers

    The request may be denied if the medical record does not document the member is ≥18 years old, the indication is not prevention of PONV, or the prescriber is not a surgeon or anesthesiologist.

    • Member age < 18 years documented or not documented
    • Indication other than prevention of postoperative nausea and vomiting or indication not documented
    • Prescriber not a surgeon or anesthesiologist or prescriber role not documented

    Initial Therapy

    Initial therapy — Authorization for initial use

    Authorization for initial use

    Initial use: Member is >=18 years, medication is for PONV, and prescribed by surgeon or anesthesiologist

    One-time authorization for one administration

    Quantity and Dosing Limits

    Aponvie (aprepitant) vial — One vial (32 mg/4.4 mL)
    Vial strength32 mg / 4.4 mL
    Quantity limitOne vial per 1 day supply (Facets RX count: 32)
    Per authorizationOne-time administration

    Site of Care Considerations

    Note

    One administration; perioperative/surgical setting implied

    Policy authorizes a single administration (one vial) and refers to perioperative use; while a specific site is not mandated, the setting implied is a perioperative/surgical (hospital outpatient) context.

    • Authorization is for one administration (one vial, 32 mg/4.4 mL)
    • Site of care is not mandated but implies perioperative/surgical (hospital outpatient) setting

    Definitions

    Aprepitant (Aponvie) — definition and mechanism (NK1 antagonist)
    Generic nameAprepitant (Aponvie)
    Mechanism of actionSelective high-affinity antagonist of human substance P / neurokinin 1 (NK1) receptors
    Clinical effectInhibits emesis via central (brain NK1 receptor) actions; crosses the blood–brain barrier

    Background

    Aponvie (aprepitant) is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors used to inhibit emesis; it crosses the blood‑brain barrier to occupy brain NK1 receptors. The agent is indicated in this policy for the prevention of postoperative nausea and vomiting (PONV).

    For use under this policy, prior authorization is required and approvals are limited to a one‑time authorization for one administration. Documentation must confirm the member is 18 years of age or older, that the medication is prescribed for prevention of PONV, and that the prescriber is a surgeon or anesthesiologist. Quantity is limited to one vial (32 mg/4.4 mL) per day.